Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Vertex study will evaluate 12-week treatment period for some hepatitis C patients

Editor's pick
Boston.com
24 October 2011
New & experimental hepatitis C treatment

Abbott says hepatitis C combo may be a blockbuster

Editor's pick
Reuters
21 October 2011
New & experimental hepatitis C treatment

Interim Phase IIb Data for Merck's VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1

Editor's pick
Market Watch (press release)
20 October 2011
New & experimental hepatitis C treatment

Sector Snap: Hepatitis C drug developers rise

Editor's pick
Bloomberg Business Week
18 October 2011
New & experimental hepatitis C treatment

Roche buys Anadys for $230 million to boost hep C business

Editor's pick
PharmaTimes
18 October 2011
Adherence

Copy of Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

Editor's pick
Kaiser Daily Global Health Policy Report
13 October 2011
Adherence

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

Editor's pick
AIDSMeds
13 October 2011
New & experimental hepatitis C treatment

Transgene Says 3 Patients in Hepatitis Trial Had Blood Disorders

Editor's pick
Bloomberg Business Week
12 October 2011
New & experimental hepatitis C treatment

Pharmasset again expands hepatitis C drug study

Editor's pick
Bloomberg BusinessWeek
11 October 2011
New & experimental hepatitis C treatment

Vertex's Hep C Drug Needs A Growth Injection

Editor's pick
The Street
11 October 2011
New & experimental HIV treatments

Boehringer signs away HIV rights to focus on hep C - InPharm

Editor's pick
InPharm
7 October 2011
New & experimental hepatitis C treatment

ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

Editor's pick
HIVandhepatitis.com
6 October 2011
Pharmaceutical industry

Bristol-Myers Is Close To Completing A Groundbreaking Hepatitis C Treatment

Editor's pick
Business Insider
3 October 2011
New & experimental hepatitis C treatment

Vertex takes early rounds of hep C bout with Merck

Editor's pick
Reuters
3 October 2011
Hepatitis C treatment

Updated Hepatitis C Practice Guidelines Now Available from AASLD

Editor's pick
Market Watch (press release)
28 September 2011
New & experimental hepatitis C treatment

J&J's hep C drug Incivo approved in Europe

Editor's pick
InPharm
22 September 2011
New & experimental hepatitis C treatment

Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes

Editor's pick
Pharmasset press release
14 September 2011
New & experimental hepatitis C treatment

Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1

Editor's pick
Pharmasset press release
7 September 2011
New & experimental hepatitis C treatment

Dramatic Changes in Hepatitis C Treatment Expected to Continue

Editor's pick
Xconomy
7 September 2011
New & experimental hepatitis C treatment

Vertex Scores Big With Hepatitis Drug

Editor's pick
Investorplace.com
1 September 2011
New & experimental hepatitis C treatment

N/A

Editor's pick
HCV New Drugs Research
29 August 2011
New & experimental hepatitis C treatment

Treatment Action Group publishes Guide to Clinical Trials for People With Hepatitis C

Editor's pick
Treatment Action Group
17 August 2011
New & experimental hepatitis C treatment

UK-Victrelis-Boceprevir HCV Drug Launched

Editor's pick
Hepatitis C New Drugs blog
10 August 2011
New & experimental hepatitis C treatment

Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks

Editor's pick
Vertex (press release)
27 July 2011